Biologically targeted therapies plus chemotherapy plus radiotherapy in stage III non-small-cell lung cancer: A case of the Icarus syndrome?

Journal of Clinical Oncology

Volumn 30, Issue 32, 2012, Pages 3909-3912

  Raben, David ^a   Bunn, Paul A ^a  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; CISPLATIN; DOCETAXEL; ERLOTINIB; ETOPOSIDE; GEFITINIB; IRINOTECAN; PACLITAXEL; PEMETREXED;

CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER STAGING; CHEMORADIOTHERAPY; DRUG EFFICACY; EDITORIAL; ESOPHAGUS DISEASE; HUMAN; LUNG NON SMALL CELL CANCER; LUNG TOXICITY; MORBIDITY; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; TRACHEOESOPHAGEAL FISTULA; TREATMENT OUTCOME;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; ESOPHAGITIS; ESOPHAGUS; FEMALE; HUMANS; LUNG NEOPLASMS; MALE;

EID: 84869441859     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2012.43.1866     Document Type: Editorial

References (44)

1. Socinski MA, Stinchcombe TE, Moore DT, et al: Incorporating bevacizumab and erlotinib in the combined-modality treatment of stage III non-small-cell lung cancer: Results of a phase I/II trial. J Clin Oncol 30:3953-3959, 2012
2. Lee JS, Scott C, Komaki R, et al: Concurrent chemoradiation therapy with oral etoposide and cisplatin for locally advanced inoperable non-small-cell lung cancer: Radiation therapy oncology group protocol 91-06. J Clin Oncol 14:1055-1064, 1996 (Pubitemid 26105509)
3. Reboul F, Brewer Y, Vincent P, et al: Concurrent cisplatin, etoposide, and radiotherapy for unresectable stage III non-small cell lung cancer: A phase II study. Int J Radiat Oncol Biol Phys 35:343-350, 1996 (Pubitemid 26158757)
4. Komaki R, Scott C, Lee JS, et al: Impact of adding concurrent chemotherapy to hyperfractionated radiotherapy for locally advanced non-small cell lung cancer (NSCLC): Comparison of RTOG 83-11 and RTOG 91-06. Am J Clin Oncol 20:435-440, 1997 (Pubitemid 27444338)
5. Choy H, Safran H, Akerley W, et al: Phase II trial of weekly paclitaxel and concurrent radiation therapy for locally advanced non-small cell lung cancer. Clin Cancer Res 4:1931-1936, 1998 (Pubitemid 28369177)
6. Furuse K, Fukuoka M, Kawahara M, et al: Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine and cisplatin in unresectable stage III non-small cell lung cancer (NSCLC). J Clin Oncol 17:2692-2699, 1999 (Pubitemid 29415225)
7. Curran WJ Jr, Paulus R, Langer CJ, et al: Sequential vs concurrent chemoradiation for stage III non-small cell lung cancer: Randomized phase III trial RTOG 9410. J Natl Cancer Inst 103:1452-1460, 2011
8. Choy H, Devore RF 3rd, Hande KR, et al: A phase II study of paclitaxel, carboplatin, and hyperfractionated radiation therapy for locally advanced inoperable non-small-cell lung cancer (a Vanderbilt Cancer Center Affiliate Network Study). Int J Radiat Oncol Biol Phys 47:931-937, 2000 (Pubitemid 30345590)
9. Gandara DR, Chansky K, Albain KS, et al: Consolidation docetaxel after concurrent chemoradiotherapy in stage IIIB non-small-cell lung cancer: Phase II Southwest Oncology Group Study S9504. J Clin Oncol 21:2004-2010, 2003 (Pubitemid 46606390)
10. Wang L, Wu S, Ou G, et al: Randomized phase II study of concurrent cisplatin/etoposide or paclitaxel/carboplatin and thoracic radiotherapy in patients with stage III non-small cell lung cancer. Lung Cancer [epub ahead of print on March 12, 2012]
11. Yamamoto N, Nakagawa K, Nishimura Y, et al: Phase III study comparing second- and third-generation regimens with concurrent thoracic radiotherapy in patients with unresectable stage III non-small-cell lung cancer: West Japan Thoracic Oncology Group WJTOG0105. J Clin Oncol 28:3739-3745, 2010
12. Govindan R, Bogart J, Stinchcombe T, et al: Randomized phase II study of pemetrexed, carboplatin, and thoracic radiation with or without cetuximab in patients with locally advanced unresectable non-small-cell lung cancer: Cancer and Leukemia Group B trial 30407. J Clin Oncol 29:3120-3125, 2011
13. Belani CP, Wang W, Johnson DH, et al: Phase III study of the Eastern Cooperative Oncology Group (ECOG 2597): Induction chemotherapy followed by either standard thoracic radiotherapy or hyperfractionated accelerated radiotherapy for patients with unresectable stage IIIA and B non-small-cell lung cancer. J Clin Oncol 23:3760-3767, 2005
14. Vokes EE, Herndon JE 2nd, Kelley MJ, et al: Induction chemotherapy followed by chemoradiotherapy compared with chemoradiotherapy alone for regionally advanced unresectable stage III non-small-cell lung cancer: Cancer and Leukemia Group B. J Clin Oncol 25:1698-1705, 2007
15. Hanna N, Neubauer M, Yiannoutsos C, et al: Phase III study of cisplatin, etoposide, and concurrent chest radiation with or without consolidation docetaxel in patients with inoperable stage III non-small-cell lung cancer: The Hoosier Oncology Group and US Oncology. J Clin Oncol 26:5755-5760, 2008
16. Rosenzweig KE, Sura S, Jackson A, et al: Involved-field radiation therapy for inoperable non small-cell lung cancer. J Clin Oncol 25:5557-5561, 2007
17. Sulman EP, Komaki R, Klopp AH, et al: Exclusion of elective nodal irradiation is associated with minimal elective nodal failure in non-small cell lung cancer. Radiat Oncol 4:5, 2009
18. Rosenman JG, Socinski MA: Does more aggressive therapy improve outcomes in the treatment of unresectable stage III non-small cell lung cancer? Semin Oncol 32:S13-S17, 2005 (suppl 3)
19. Stinchcombe TE, Morris DE, Lee CB, et al: Induction chemotherapy with carboplatin, irinotecan, and paclitaxel followed by high dose three-dimension conformal thoracic radiotherapy (74 Gy) with concurrent carboplatin, paclitaxel, and gefitinib in unresectable stage IIIA and stage IIIB non-small cell lung cancer. J Thorac Oncol 3:250-257, 2008 (Pubitemid 351654324)
20. Stinchcombe TE, Hodgson L, Herndon JE 2nd, et al: Treatment outcomes of different prognostic groups of patients on Cancer and Leukemia Group B trial 39801: Induction chemotherapy followed by chemoradiotherapy compared with chemoradiotherapy alone for unresectable stage III non-small cell lung cancer. J Thorac Oncol 4:1117-1125, 2009
21. Socinski MA, Blackstock AW, Bogart JA, et al: Randomized phase II trial of induction chemotherapy followed by concurrent chemotherapy and dose-escalated thoracic conformal radiotherapy (74 Gy) in stage III non-small-cell lung cancer: CALGB 30105. J Clin Oncol 26:2457-2463, 2008
22. Salama JK, Stinchcombe TE, Gu L, et al: Pulmonary toxicity in stage III non-small cell lung cancer patients treated with high-dose (74 Gy) 3-dimensional conformal thoracic radiotherapy and concurrent chemotherapy following induction chemotherapy: A secondary analysis of Cancer and Leukemia Group B (CALGB) trial 30105. Int J Radiat Oncol Biol Phys 81:e269-e274, 2011
23. Bradley JD, Bae K, Graham MV, et al: Primary analysis of the phase II component of a phase I/II dose intensification study using three-dimensional conformal radiation therapy and concurrent chemotherapy for patients with inoperable non-small-cell lung cancer: RTOG 0117. J Clin Oncol 28:2475-2480, 2010
24. Bradley JD, Paulus R, Komaki R, et al: Randomized phase III comparison of standard-dose (60 Gy) versus high-dose (74 Gy) conformal chemoradiotherapy with or without cetuximab for stage IIIA/IIIB non-small cell lung cancer: Preliminary findings on radiation dose in RTOG 0617. 53rd Annual American Society for Radiation Oncology Meeting, Miami Beach, FL, October 2-6, 2011 (abstr LBA2)
25. Ettinger DS, Akerley W, Bepler G, et al: Non-small cell lung cancer. J Natl Compr Canc Netw 8:740-801, 2010
26. Raben D, Helfrich B, Chan DC, et al: The effects of cetuximab alone and in combination with radiation and/or chemotherapy in lung cancer. Clin Cancer Res 11:795-805, 2005 (Pubitemid 40116908)
27. Frederick BA, Helfrich BA, Coldren CD, et al: Epithelial to mesenchymal transition predicts gefitinib resistance in cell lines of head and neck squamous cell carcinoma and non-small cell lung carcinoma. Mol Cancer Ther 6:1683-1691, 2007 (Pubitemid 46954044)
28. Helfrich BA, Raben D, Varella-Garcia M, et al: Antitumor activity of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor gefitinib (ZD1839, Iressa) in non-small cell lung cancer cell lines correlates with gene copy number and EGFR mutations but not EGFR protein levels. Clin Cancer Res 12:7117-7125, 2006 (Pubitemid 44974512)
29. Witta SE, Dziadziuszko R, Yoshida K, et al: ErbB-3 expression is associated with E-cadherin and their co-expression restores response to gefitinib in nonsmall- cell lung cancer (NSCLC). Ann Oncol 20:689-695, 2009
30. Dziadziuszko R, Witta SE, Cappuzzo F, et al: Epidermal growth factor receptor messenger RNA expression, gene dosage, and gefitinib sensitivity in non-small cell lung cancer. Clin Cancer Res 12:3078-3084, 2006 (Pubitemid 43837354)
31. Rothschild S, Bucher SE, Bernier J, et al: Gefitinib in combination with irradiation with or without cisplatin in patients with inoperable stage III non-small cell lung cancer: A phase I trial. Int J Radiat Oncol Biol Phys 80:126-132, 2011
32. Ready N, Jänne PA, Bogart J, et al: Chemoradiotherapy and gefitinib in stage III non-small cell lung cancer with epidermal growth factor receptor and KRAS mutation analysis: Cancer and Leukemia Group B (CALGB) 30106, a CALGB-stratified phase II trial. J Thorac Oncol 5:1382-1390, 2010
33. Center B, Petty WJ, Ayala D, et al: A phase I study of gefitinib with concurrent dose-escalated weekly docetaxel and conformal three-dimensional thoracic radiation followed by consolidative docetaxel and maintenance gefitinib for patients with stage iii non-small cell lung cancer. J Thorac Oncol 5:69-74, 2010
34. Kelly K, Chansky K, Gaspar LE, et al: Phase III trial of maintenance gefitinib or placebo after concurrent chemoradiotherapy and docetaxel consolidation in inoperable stage III non-small-cell lung cancer: SWOG S0023. J Clin Oncol 26:2450-2456, 2008
35. Chang CC, Chi KH, Kao SJ, et al: Upfront gefitinib/erlotinib treatment followed by concomitant radiotherapy for advanced lung cancer: A monoinstitutional experience. Lung Cancer 73:189-194, 2011
36. Williams KJ, Telfer BA, Brave S, et al: ZD6474, a potent inhibitor of vascular endothelial growth factor signaling, combined with radiotherapy: Schedule-dependent enhancement of antitumor activity. Clin Cancer Res 10:8587-8593, 2004 (Pubitemid 40053426)
37. Shibuya K, Komaki R, Shintani T, et al: Targeted therapy against VEGFR and EGFR with ZD6474 enhances the therapeutic efficacy of irradiation in an orthotopic model of human non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 69:1534-1543, 2007 (Pubitemid 350116420)
38. Schutz FA, Je Y, Richards CJ, et al: Meta-analysis of randomized controlled trials for the incidence and risk of treatment-related mortality in patients with cancer treated with vascular endothelial growth factor tyrosine kinase inhibitors. J Clin Oncol 30:871-877, 2012
39. Zhu J, Sharma DB, Gray SW, et al: Carboplatin and paclitaxel with vs without bevacizumab in older patients with advanced non-small cell lung cancer. JAMA 307:1593-1601, 2012
40. Solomon B, Varella-Garcia M, Camidge DR: ALK gene rearrangements: A new therapeutic target in a molecularly defined subset of non-small cell lung cancer. J Thorac Oncol 4:1450-1454, 2009
41. Shaw AT, Yeap BY, Solomon BJ, et al: Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: A retrospective analysis. Lancet Oncol 12:1004-1012, 2011
42. Kim ES, Herbst RS, Wistuba II, et al: The BATTLE trial: Personalizing therapy for lung cancer. Cancer Discov 1:44-53, 2011
43. Garnett MJ, Edelman EJ, Heidorn SJ, et al: Systematic identification of genomic markers of drug sensitivity in cancer cells. Nature 483:570-575, 2012
44. Janne PA, Wang X, Socinski MA, et al: Randomized phase II trial of erlotinib alone or with carboplatin and paclitaxel in patients who were never or light former smokers with advanced lung adenocarcinoma: CALGB 30406 Trial. J Clin Oncol 30:2063-2069, 2012